USBC (USBC)
XASE:USBC
Top Page
USBC
(NYSE MKT:USBC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.34
▼(-28.69% Downside)
Action:ReiteratedDate:04/03/26
The score is held down primarily by weak financial performance (material losses, negative EBIT, and ongoing cash burn with limited revenue visibility) and bearish technicals (price below key moving averages and negative MACD). Offsetting factors include a currently low-debt balance sheet and moderately positive corporate developments (NYSE compliance restoration and business divestiture/strategic focus), but these are not enough to overcome the profitability and cash-flow risks.
Positive Factors
Low leverage / balance sheet strength
The company’s very low reported debt relative to equity provides structural financial flexibility, reducing interest burden and giving management runway to fund product development or absorb setbacks without immediate refinancing. This supports multi-month execution of pilots and strategic initiatives.
Negative Factors
Sustained negative cash flow
Persistent negative operating and free cash flow indicates the business is not self-funding and will need external capital to continue operations. Over months this drains optionality, risks dilution or costly financing, and constrains investment in commercialization or regulatory-compliance activities.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet strength
The company’s very low reported debt relative to equity provides structural financial flexibility, reducing interest burden and giving management runway to fund product development or absorb setbacks without immediate refinancing. This supports multi-month execution of pilots and strategic initiatives.
Read all positive factors
USBC (USBC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$130.69M
Dividend YieldN/A
Average Volume (3M)608.13K
Price to Earnings (P/E)―
Beta (1Y)2.51
Revenue GrowthN/A
EPS Growth55.04%
CountryUS
Employees11
SectorTechnology
Sector Strength88
IndustryHardware, Equipment & Parts
Share Statistics
EPS (TTM)-0.07
Shares Outstanding388,144,440
10 Day Avg. Volume280,969
30 Day Avg. Volume608,129
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.87
Price to Sales (P/S)0.00
P/FCF Ratio-11.12
Enterprise Value/Market Cap-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.30
Enterprise Value/Ebitda0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.8
Revenue Forecast (FY)$6.00M
USBC Business Overview & Revenue Model
Company Description
USBC, Inc., together with its subsidiaries, operates in digital financial technologies business in United States. The company develops transformative financial services, including digital assets, banking solutions, and non-invasive health monitori...
USBC Earnings Call Summary
Earnings Call Date:May 15, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:May 20, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of promising technological advancements and clinical results, coupled with financial challenges and a need for further capital. The company is making significant strides in product development and intellectual property, but faces issues with cash reserves and shareholder equity.Positive Updates
Gen 2 Device Development - KnowU
The KnowU, a wearable noninvasive continuous glucose monitoring device, was announced on February 27. It is significantly smaller, lighter, includes onboard computing power, and built-in machine learning capabilities.
Negative Updates
Negative Shareholder Equity
Shareholder equity for Q2 fiscal 2024 was a negative $1.75 million versus $3.74 million in fiscal '23 ending September 30, 2023.
Read all updates
Q2-2024 Updates
Positive
Negative
Gen 2 Device Development - KnowU
The KnowU, a wearable noninvasive continuous glucose monitoring device, was announced on February 27. It is significantly smaller, lighter, includes onboard computing power, and built-in machine learning capabilities.
Read all positive updates
Company Guidance
During the Know Labs Q2 2024 earnings call, the company provided several updates and guidance on its progress across key work streams. The company highlighted the development of its Generation 1 and Generation 2 (KnowU) noninvasive continuous glucose monitoring devices, with the latter being smaller, lighter, and equipped with built-in machine learning capabilities. Clinical trials have been promising, with a mean absolute relative difference (MARD) of 11.1% achieved, and plans to improve this to 10% or less. Financially, Know Labs reported an operating loss of $4.73 million, a slight improvement from the previous year, and maintained a cash balance of $4.71 million as of March 31, 2024. The company has secured up to $12 million in funding to support its core work streams and plans to raise additional funds through equity offerings to address its negative shareholder equity of $1.75 million. Know Labs is also actively expanding its intellectual property portfolio, with over 300 patents issued or pending globally. The company is positioning itself to achieve FDA clearance and commercialize its innovative glucose monitoring technology while exploring international opportunities.USBC Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 4.36M | 0.00 |
| Gross Profit | -150.48K | -150.59K | -270.17K | -313.02K | 4.04M | -200.81K |
| EBITDA | -32.26M | -17.90M | -14.95M | -13.71M | -12.25M | -10.25M |
| Net Income | -44.91M | -22.12M | -16.58M | -15.29M | -20.07M | -25.36M |
Balance Sheet | ||||||
| Total Assets | 93.67M | 125.08M | 3.66M | 8.27M | 13.76M | 12.89M |
| Cash, Cash Equivalents and Short-Term Investments | 4.09M | 8.82M | 3.11M | 8.02M | 12.59M | 12.26M |
| Total Debt | 234.82K | 342.79K | 5.08M | 2.92M | 2.56M | 9.91M |
| Total Liabilities | 12.14M | 27.96M | 5.82M | 4.52M | 3.90M | 11.65M |
| Stockholders Equity | 81.53M | 97.12M | -2.16M | 3.74M | 9.86M | 1.24M |
Cash Flow | ||||||
| Free Cash Flow | -10.33M | -7.60M | -12.90M | -10.43M | -7.78M | -7.15M |
| Operating Cash Flow | -10.33M | -7.60M | -12.83M | -10.35M | -6.92M | -6.85M |
| Investing Cash Flow | 0.00 | 0.00 | -66.35K | -80.80K | -855.47K | -299.52K |
| Financing Cash Flow | 13.39M | 13.31M | 7.98M | 5.86M | 8.11M | 15.11M |
USBC Technical Analysis
Negative
0.48
Price Trends
0.42
Negative
0.56
Negative
1.09
Negative
Market Momentum
-0.02
Negative
42.41
Neutral
12.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USBC, the sentiment is Negative. The current price of 0.480979 is above the 20-day moving average (MA) of 0.36, above the 50-day MA of 0.42, and below the 200-day MA of 1.09, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 42.41 is Neutral, neither overbought nor oversold. The STOCH value of 12.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for USBC.
USBC Risk Analysis
USBC disclosed 33 risk factors in its most recent earnings report. USBC reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
USBC Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
53 Neutral | $663.07M | -13.49 | -70.17% | ― | 36.85% | -77.93% | |
52 Neutral | $1.01B | -42.67 | 12.97% | ― | ― | ― | |
47 Neutral | $79.08M | -0.64 | -657.41% | ― | -27.81% | 26.81% | |
46 Neutral | $101.26M | ― | -49.95% | ― | 71.92% | 31.84% | |
45 Neutral | $191.61M | -1.68 | -137.37% | ― | -67.66% | 13.39% | |
44 Neutral | $130.69M | -2.24 | -46.59% | ― | ― | 55.04% |
* Technology Sector Average
USBC
USBC
0.34
-0.17
-33.86%
LPTH
Lightpath Technologies
11.49
9.84
596.36%
MVIS
Microvision
0.63
-0.49
-43.69%
KULR
KULR Technology Group
2.19
-6.85
-75.77%
SLNH
Soluna Holdings
0.71
0.31
77.50%
SATL
Satellogic
7.05
4.01
131.91%
USBC Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
USBC Divests Legacy Sensor Unit to Focus on Fintech
Positive
Apr 2, 2026
USBC, Inc. is a publicly traded technology company focused on transformative financial services, including digital assets and banking solutions, with a key emphasis on developing a U.S.-dollar denominated tokenized deposit that runs on blockchain ...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
USBC Regains NYSE American Compliance After Equity Remediation
Positive
Mar 31, 2026
On March 27, 2026, USBC, Inc. regained full compliance with all NYSE American continued listing standards, resolving stockholders’ equity deficiencies first identified by the exchange on September 27, 2024. The exchange has removed the ̶...
Business Operations and StrategyExecutive/Board Changes
USBC Reprices Stock Options to Refresh Equity Incentives
Neutral
Mar 24, 2026
On March 18, 2026, USBC’s board approved the repricing of all 83.0 million outstanding stock options under its Amended and Restated 2021 Equity Incentive Plan, resetting the exercise price to $0.37 per share, the closing price of the company...
Business Operations and StrategyProduct-Related Announcements
USBC Begins Pilot Phase for Tokenized Deposit Launch
Neutral
Mar 10, 2026
USBC, Inc. has begun Phase 1 of a multi-stage delivery strategy to launch its USBC tokenized deposit product, starting with an extended pilot involving a limited group of internal employees in a non-production environment. The results from this in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.